2026-08-12

Accepted for Both Oral Presentation and Poster! Two Great Bay Bio Technology Advancements Enabling Antibody R&D for Obesity Targets Selected for Obesity Week® 2026

2026-08-07

AlfaCell Platform Enables Client’s Out-Licensed Pipeline to Successfully Enter Phase II Clinical Trials, Advancing Novel Drugs and Biosimilars in Parallel

2026-07-17

Platform Case | AI Tackles Challenging GPCR Drug Target in 8 Months! AlfaBodY Platform of Great Bay Bio Generates Long-Acting Non-Rebound Weight-Loss Antibody; Research Findings Published

2026-06-25

Technology Platform | AlfaBodY Intelligent Molecular Design Platform Powers New Drug R&D: Deliver PCC+ in 8 Months and Conquer Hard-to-Drug Targets

2026-06-10

Tech Platform | AlfaDAX Platform Iteratively Optimizes Nanobodies, Delivering a 10-Fold Affinity Improvement in 1.5 Months

2026-06-03

Technology Platform | AI-Enabled Antibody Molecular Engineering: Iterative Optimization of the AlfaDAX Platform Breaks Through Traditional R&D Bottlenecks

2026-05-20

Great Bay Bio Establishes Strategic Partnership with a Global Leading Biosimilar Enterprise to Accelerate Global Adoption of AlfaCell Platform

2026-03-27

Great Bay Bio’s AlfaCell Delivers Average Titer Above 6.9 g/L Across Client Projects, with RCB Completed in Just 1.5 Months

2026-03-26

Great Bay Bio Recognized in the Deloitte Greater Bay Area Technology Fast 40 & Rising Star Program, Receiving Further Authoritative Recognition for AI-Enabled Bioprocess Innovation

2026-03-09

Great Bay Bio’s CHO-K1 Catalog Medium AlfaMedX- K1 (Growth Factor–Free) Achieves FDA DMF Filing